Press Releases

Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 10, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and six months ended June 30, 2017 and provide important corporate updates on Wednesday, August 16 th.

BrainStorm Cell Therapeutics

Wednesday, August 16, 2017 @ 8:30am Eastern Time 
Toll Free:                   877-718-5095 
Israel Investors:        1 80 924 6042 
International:             913-312-0381 
Conference ID:          1392963 

Replays, available through August 30, 2017 
Toll Free:                   844-512-2921 
International:             412-317-6671 
Conference ID:          1392963

About BrainStorm Cell Therapeutics Inc. 
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at


Uri Yablonka 
Chief Business Officer 
Brainstorm Cell Therapeutics Inc. 
Phone: (646) 666-3188

Michael Rice 
LifeSci Advisors, LLC 
Phone: 646-597-6979


View original content:

SOURCE BrainStorm Cell Therapeutics Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds